Sign in
Active, not recruitingPhase 3

Facilitating Rapid Naltrexone Initiation

Key facts

Who runs it
New York State Psychiatric Institute
Where
New York, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
100 people, planned
Started
25 Nov 2017
Ended
Oct 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • CI-581-a
  • CI-581-b
Record updated
2 February 2024

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • DSM-5 criteria of current opioid use disorder present for at least six months, supported by a positive urine for opioids or a positive naloxone challenge test
  • Aged 18 to 70 years
  • In otherwise good health based on complete medical history, physical examination, vital signs measurement, ECG, and laboratory tests (hematology, blood chemistry, urinalysis) within normal ranges
  • Able to give written informed consent to participate in the study
  • Interested in maintenance treatment with extended-release naltrexone

Who cannot take part

  • On psychotropic or other medications that may interact adversely with study medications, or whose effect might be disrupted by study medications
  • Concurrent participation in another treatment study or another substance abuse program with the exception of a self-help group
  • Ongoing chronic pain that may require opioid management, or for which surgery is indicated
  • Active, or past, psychiatric disorder(s) which might interfere with participation or make participation hazardous, including DSM-V mental disorder due to another medical condition, major depressive disorder, psychotic disorder, or bipolar disorder with psychotic features
  • History of allergy or sensitivity to any study medication
  • History of inability to tolerate study medications
  • History of a use disorder with the study medications
  • For women of childbearing potential: positive serum pregnancy test, lactation, or unwillingness to use a satisfactory method of birth control
  • Unstable physical disorders which might make participation hazardous such as hypertension (>160/90), anemia, active hepatitis or other liver disease (transaminase levels < 2-3 X the upper limit of normal will be considered acceptable), or untreated diabetes. Participants reporting HIV+ status will be asked to provide information about their current treatment, including all medications. Participants who are on the antiretroviral ritonavir (Norvir) will be excluded due to the possibility that the study medications in combination with this medication may increase the risk of drug-induced hepatitis
  • Acute hepatitis with SGOT or SGPT > 3 times the upper end of the laboratory normal range
  • Physiologically dependent on alcohol or sedative-hypnotics with impending withdrawal requiring medical management
  • Methadone maintenance treatment or regular use of illicit methadone (>30 mg per week); urine toxicology positive for methadone at admission
  • Buprenorphine maintenance treatment or regular use of buprenorphine (>16 mg per week); urine toxicology positive for buprenorphine at admission
  • Significant current suicidal risk or a suicide attempt within the past year

Where in United States

  • New York State Psychiatric InstituteNew York, United States

About the trial

What the trial wants to find out

The incidence of opioid use disorders (OUDs) has increased to near-epidemic proportions. While maintenance with long-acting opioids such as methadone or buprenorphine represents an effective treatment strategy, it may be unacceptable to many individuals. As a result, long-acting injectable naltrexone (XR-NTX), an antagonist medication that blocks the effects of opioids for at least 4 weeks, is now indicated for relapse prevention following detoxification. This randomized, controlled trial aims to test the efficacy of a glutamate modulator at facilitating a rapid non-opioid based naltrexone induction.

The 2 groups in the trial

  • CI-581aTreatment being tested

    CI-581a will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated. (0.11 mg/kg 2-min bolus followed by 1.3 mg/kg over 90 min)

    Treatment: CI-581-a

  • CI-581bPlacebo, for comparison

    CI-581b will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated. (2-min saline bolus followed by 0.0125 mg/kg over 90 min)

    Treatment: CI-581-b

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Glutamatergic Modulation to Facilitate Naltrexone Initiation: A Randomized, Controlled Trial
Record updated
2 February 2024